CDC’s Vaccine Safety Datalink (VSD) met the statistical criteria to prompt additional investigation into whether there was a safety concern for ischemic stroke in people ages 65 and older who received the Pfizer-BioNTech COVID-19 Vaccine,
xiaozuiba(xiaozuiba)
Bivalent. To date, no other safety systems have shown a similar signal and multiple subsequent analyses have not validated this signal. No change is recommended in COVID-19 vaccination practice.
CDC’s Vaccine Safety Datalink (VSD) met the statistical criteria to prompt additional investigation into whether there was a safety concern for ischemic stroke in people ages 65 and older who received the Pfizer-BioNTech COVID-19 Vaccine,
-xiaozuiba(xiaozuiba);
2023-1-13{194}(#15106020@0)
Bivalent. To date, no other safety systems have shown a similar signal and multiple subsequent analyses have not validated this signal. No change is recommended in COVID-19 vaccination practice.